Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Asset Writedowns and Impairment (2021 - 2025)

Historic Asset Writedowns and Impairment for Biofrontera (BFRI) over the last 5 years, with Q3 2025 value amounting to $13000.0.

  • Biofrontera's Asset Writedowns and Impairment fell 6176.47% to $13000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $7000.0, marking a year-over-year decrease of 9066.67%. This contributed to the annual value of $162000.0 for FY2024, which is 3278.69% up from last year.
  • Biofrontera's Asset Writedowns and Impairment amounted to $13000.0 in Q3 2025, which was down 6176.47% from -$11000.0 recorded in Q2 2025.
  • In the past 5 years, Biofrontera's Asset Writedowns and Impairment ranged from a high of $94000.0 in Q3 2023 and a low of -$46000.0 during Q1 2025
  • Over the past 5 years, Biofrontera's median Asset Writedowns and Impairment value was $13000.0 (recorded in 2025), while the average stood at $20526.3.
  • The largest annual percentage gain for Biofrontera's Asset Writedowns and Impairment in the last 5 years was 920000.0% (2022), contrasted with its biggest fall of 120000.0% (2022).
  • Over the past 5 years, Biofrontera's Asset Writedowns and Impairment (Quarter) stood at $8000.0 in 2021, then crashed by 162.5% to -$5000.0 in 2022, then tumbled by 620.0% to -$36000.0 in 2023, then skyrocketed by 241.67% to $51000.0 in 2024, then crashed by 74.51% to $13000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at $13000.0 for Q3 2025, versus -$11000.0 for Q2 2025 and -$46000.0 for Q1 2025.